BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

Simona Soverini; Margherita Martelli; Luana Bavaro; Caterina De Benedittis; Simona Sica; Federica Sorà; Alessandra Iurlo; Massimiliano Bonifacio; Patrizia Pregno; Sara Galimberti; Francesca Lunghi; Francesco Albano; Mariella D'Adda; Monica Crugnola; Isabella Capodanno; Fausto Castagnetti; Gabriele Gugliotta; Cristina Papayannidis; Gianantonio Rosti; Antonio Percesepe; Flavio Mignone; Michele Baccarani; Giovanni Martinelli; Michele Cavo

doi:10.1038/s41375-020-01098-w

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

Leukemia. 2021 Jul;35(7):2102-2107. doi: 10.1038/s41375-020-01098-w. Epub 2020 Dec 1.

Authors

Simona Soverini¹, Margherita Martelli², Luana Bavaro², Caterina De Benedittis², Simona Sica³, Federica Sorà³, Alessandra Iurlo⁴, Massimiliano Bonifacio⁵, Patrizia Pregno⁶, Sara Galimberti⁷, Francesca Lunghi⁸, Francesco Albano⁹, Mariella D'Adda¹⁰, Monica Crugnola¹¹, Isabella Capodanno¹², Fausto Castagnetti^{13

14}, Gabriele Gugliotta^{13

14}, Cristina Papayannidis^{13

14}, Gianantonio Rosti^{13

14}, Antonio Percesepe¹⁵, Flavio Mignone¹⁶, Michele Baccarani², Giovanni Martinelli^{2

17}, Michele Cavo^{13

14}

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy. simona.soverini@unibo.it.
² Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
³ Fondazione Policlinico Universitario A Gemelli-IRCCS, Istituto di Ematologia e Università Cattolica del Sacro Cuore, Rome, Italy.
⁴ Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
⁵ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
⁶ Hematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Turin, Italy.
⁷ Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
⁸ Hematology and BMT Unit, San Raffaele Scientific Institute IRCCS, Milan, Italy.
⁹ Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Bari, Italy.
¹⁰ Hematology Unit, Spedali Civili Azienda Ospedaliera, Brescia, Italy.
¹¹ Division of Hematology, Azienda Ospedialiero-Universitaria, Parma, Italy.
¹² Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.
¹³ Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italia.
¹⁴ Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italia.
¹⁵ Unit of Medical Genetics, University of Parma, Parma, Italy.
¹⁶ Department of Science and Innovation Technology (DISIT), University of Piemonte Orientale, Alessandria, Italy.
¹⁷ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

PMID: 33262525
DOI: 10.1038/s41375-020-01098-w

No abstract available

MeSH terms

Drug Resistance, Neoplasm / genetics*
Fusion Proteins, bcr-abl / genetics*
High-Throughput Nucleotide Sequencing / methods
Humans
Leukemia / drug therapy*
Leukemia / genetics*
Philadelphia Chromosome / drug effects*
Prevalence
Protein Kinase Inhibitors / pharmacology*
Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

BCR-ABL1 fusion protein, human
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Fusion Proteins, bcr-abl